We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » GENERIC INDUSTRY WANTS CLARITY ON CORRECTING PATENTS, DEFINING 'LISTED DRUG'
GENERIC INDUSTRY WANTS CLARITY ON CORRECTING PATENTS, DEFINING 'LISTED DRUG'
May 18, 2004
The FDA should add regulatory language to rules governing brand-generic competition that would expressly require a brand firm to correct or delete patent information when a court order requires such a patent change, the Generic Pharmaceutical Association (GPhA) said in comments suggesting changes in FDA drug patent rules.